RAB22A and cancer: These findings reveal the lysosomal degradation mechanism of Rab22a-neoF1 fusion protein and suggest that Sorafenib and Regorafenib could be effective drugs for cancer patients expressing the RAB22A-NeoF1 fusion gene.